Literature DB >> 22168640

The risks and benefits of indacaterol--the FDA's review.

Badrul A Chowdhury1, Sally M Seymour, Theresa M Michele, Anthony G Durmowicz, Dongmei Liu, Curtis J Rosebraugh.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 22168640     DOI： 10.1056/NEJMp1109621

Source DB:  PubMed          Journal:  N Engl J Med        ISSN： 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  16 in total

Review 1.  Role of indacaterol, a once-daily bronchodilator, in chronic obstructive pulmonary disease.

Authors:  Heemesh D Seth; Samir Sultan; Mark H Gotfried
Journal:  J Thorac Dis       Date:  2013-12       Impact factor: 2.895

Review 2.  Indacaterol: a review of its use as maintenance therapy in patients with chronic obstructive pulmonary disease.

Authors:  Kate McKeage
Journal:  Drugs       Date:  2012-03-05       Impact factor: 9.546

Review 3.  Turning a molecule into a medicine: the development of indacaterol as a novel once-daily bronchodilator treatment for patients with COPD.

Authors:  Lorraine Murphy; Stephen Rennard; James Donohue; Mathieu Molimard; Ronald Dahl; Kai-Michael Beeh; Juergen Dederichs; Hans-Jürgen Fülle; Mark Higgins; David Young
Journal:  Drugs       Date:  2014-09       Impact factor: 9.546

Review 4.  Systems pharmacology, pharmacogenetics, and clinical trial design in network medicine.

Authors:  Elliott Antman; Scott Weiss; Joseph Loscalzo
Journal:  Wiley Interdiscip Rev Syst Biol Med       Date:  2012-05-11

Review 5.  Improving the quality of life in patients with chronic obstructive pulmonary disease: focus on indacaterol.

Authors:  Gregory J Feldman
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2013-02-14

Review 6.  Combination bronchodilator therapy in the management of chronic obstructive pulmonary disease.

Authors:  Donald P Tashkin; Gary T Ferguson
Journal:  Respir Res       Date:  2013-05-08

7.  Randomised, double-blind, placebo-controlled crossover study to investigate different dosing regimens of olodaterol delivered via Respimat® in patients with moderate to severe persistent asthma.

Authors:  Kai-Michael Beeh; Craig LaForce; Martina Gahlemann; Arne Wenz; Robert Toorawa; Matjaž Fležar
Journal:  Respir Res       Date:  2015-07-16

Review 8.  Indacaterol for chronic obstructive pulmonary disease: systematic review and meta-analysis.

Authors:  Vincent C H Chung; Polly H X Ma; David S C Hui; Wilson W S Tam; Jin Ling Tang
Journal:  PLoS One       Date:  2013-08-14       Impact factor: 3.240

Review 9.  Positioning new pharmacotherapies for COPD.

Authors:  Igor Z Barjaktarevic; Anthony F Arredondo; Christopher B Cooper
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2015-07-24

Review 10.  Indacaterol: a comprehensive review.

Authors:  Andrea Rossi; Guido Polese
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2013-07-25
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.